Lupin Launches Mirabegron tablets

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

Friday, May 3, 2024

Asian Paints

2927.50

(-1.56%)

Axis Bank

1141.05

(-0.76%)

Bajaj Finance

6932.80

(0.75%)

Bajaj Finserv

1627.10

(0.69%)

Bharti Airtel

1276.75

(-2.25%)

HCL Technologi..

1347.80

(-0.93%)

HDFC Bank

1518.65

(-0.94%)

Hind. Unilever

2215.50

(-0.45%)

ICICI Bank

1142.00

(0.18%)

IndusInd Bank

1482.70

(-1.53%)

Infosys

1416.45

(0.11%)

ITC

436.25

(-0.65%)

JSW Steel

873.30

(-1.94%)

Kotak Mah. Ban..

1547.25

(-1.81%)

Larsen & Toubr..

3499.10

(-2.74%)

M & M

2192.95

(0.39%)

Maruti Suzuki

12491.15

(-2.37%)

Nestle India

2455.60

(-2.22%)

NTPC

365.10

(-1.15%)

Power Grid Cor..

310.70

(-0.88%)

Reliance Indus..

2868.50

(-2.17%)

St Bk of India

831.55

(0.18%)

Sun Pharma.Ind..

1508.40

(-0.66%)

Tata Motors

1013.80

(-1.38%)

Tata Steel

166.45

(-0.54%)

TCS

3839.35

(-0.63%)

Tech Mahindra

1249.65

(-1.36%)

Titan Company

3535.40

(-0.96%)

UltraTech Cem.

9816.75

(-1.65%)

Wipro

456.85

(-0.09%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Lupin Launches Mirabegron tablets	Share Back
(22 Apr 2024)
Mirabegron extended-release tablets, 25 mg is a generic equivalent of Myrbetriq extended-release tablets, 25 mg of Astellas Pharma Global Development, Inc. It is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. As per IQVIA MAT February 2024, Mirabegron extended-release tablets USP 25mg and 50mg had annual sales of $2.42billion in the United States. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The drug major reported consolidated net profit of Rs 613.12 crore in Q3 FY24, steeply higher from Rs 153.47 crore posted in Q3 FY23. Revenue from operations jumped 19.67% year on year to Rs 5,079.9 crore during the quarter. The scrip fell 2.92% to end at Rs 1,547.05 on Friday, 19 April 2024.
Top